29.11.2012 - Nestlé Health Science SA and Chi-Med have agreed to form a 50/50 joint venture, to be named Nutrition Science Partners Limited.
The Swiss entity and the subsidiary of Hutchinson Whampoa Ltd. (Hong Kong) will fuse their knowledge in drug development and nutrition to develop and market nutritional healthcare products for gastrointestinal indications (GI) which can be extended to metabolic and brain health areas in the future. Under the terms of the agreement, the Nestlé subsidiary will make an initial capital investment in return for the its 50% shareholding in Nutrition Science Partners. Chi-Med in turn will provide exclusive rights to screen its botanical compound library, and its botanical R&D platform. Chi-Meds library contains more than 1,500 purified natural products and over 50,000 plant extracts from some 1,200 diverse medicinal plants.
“This Joint Venture provides Nestlé Health Science with an opportunity to develop and commercialise truly innovative and scientifically validated botanical based nutrition solutions for personalised healthcare in gastrointestinal health. Whilst Nestlé Health Science will bring unique competencies in nutritional sciences, diagnostics and commercial capabilities, Chi-Med will provide their best-in-class Traditional Chinese Medicine library and discovery platform, which will be the basis of Nutrition Science Partner’s future GI pipeline.“
The new company will also initiate Phase III trails in 2013 with HMPL-004, the lead candidate of Chi-Med’s subsidiary Hutchinson MediPharma Ltd., in 2,700 patients with inflammatory bowel diseases such as Morbus Crohn and Colitis ulcerosa. Nutrition Science Partners will be funded through Nestlé Health Science’s investment and milestone payments. Louis Cantarell will bet he Chairman of the company, and Christian Hogg will be both Director and General Manager.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
Merck’s advanced water purification system with new high-throughput line delivers up to 9,000 liters of pure water daily with real-time monitoring and ensures constant water quality with low and predictable running costs. more